Watson-Marlow Pumps Group is unveiling a new range of 400RXMD panel-mount pumps designed specifically to meet the demands from medical device specialists serving the surgical ablation market. Unique performance and robust modern design ...
Tags: New Generation Pumps, Medical Applications, Watson-Marlow Pumps Group
The Federal Institute for Drugs and Medical Devices, the German regulatory authority, has approved Helix BioPharma's clinical trial application for a European Phase III efficacy trial of Topical Interferon Alpha-2b in patients with ...
Amorfix Life Sciences and CNJ Holdings have signed an agreement to identify and develop therapeutic antibodies targeting disease specific epitopes (DSEs). The collaboration will make use of Amorfix's ProMIS discovery technology and the ...
Tags: Amorfix Life Sciences, CNJ Holdings, agreement, disease specific epitopes
Proacta, a San Diego based biotechnology company, has announced FDA approval of investigational new drug (IND) application for PR610, a hypoxia-activated irreversible multi-kinase inhibitor, for the treatment of cancer. With the IND ...
Tags: investigational new drug, IND
GlaxoSmithKline (GSK) has received FDA approval for Votrient (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The approval is based on the results of the randomized, ...
Tags: advanced soft tissue sarcoma, STS, soft tissue sarcomas, GlaxoSmithKline
NewLink Genetics has received a notice of allowance for a Japanese patent entitled, Antitumor Vaccination Using Allogeneic Tumor Cells Expressing Alpha (1,3)-Galactosyltransferase. The patent contains pharmaceutical composition claims ...
Tags: NewLink Genetics, galactosyltransferase, antitumor vaccination
The Canadian Intellectual Property Office has issued a patent for Lorus Therapeutics' cancer immunotherapy agent, IL-17E. The patent protects the use of IL-17E to treat cancer, including solid tumors such as colon, breast, ovarian, ...
Tags: patent, IL-17E, treatment of cancer
Genmab and GlaxoSmithKline (GSK) have announced the submission of a new drug application (NDA) for Arzerra (ofatumumab) to the Japanese Ministry of Health, Labor and Welfare (MHLW). Arzerra (ofatumumab) is submitted for the approval ...
Tags: new drug application, Arzerra, chronic lymphocytic leukemia